851. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design
- Author
-
Ricardo A. Mata, Holger Stark, Ashwin Chari, Kai Tittmann, Gleb Bourenkov, Thomas R. Schneider, Fabian Henneberg, and Jil Schrader
- Subjects
Boron Compounds ,Threonine ,0301 basic medicine ,Proteasome Endopeptidase Complex ,Protein Conformation ,Stereochemistry ,Glycine ,Antineoplastic Agents ,Peptide ,Crystallography, X-Ray ,20s proteasome ,Bortezomib ,03 medical and health sciences ,0302 clinical medicine ,Protein structure ,Catalytic Domain ,medicine ,Humans ,Angstrom ,chemistry.chemical_classification ,Multidisciplinary ,Mechanism (biology) ,Cancer ,medicine.disease ,Boronic Acids ,3. Good health ,030104 developmental biology ,Proteasome ,chemistry ,Drug Design ,030220 oncology & carcinogenesis ,Biocatalysis ,Cancer research ,Proteasome Inhibitors ,medicine.drug - Abstract
Insights into proteasome inhibition Proteasomes are large protein complexes that degrade and remove proteins to maintain proper cellular physiology and growth. Proteasomes are a validated target for anticancer therapy, but drug design has been hampered by poor understanding of how inhibitors interact with the active site. Schrader et al. succeeded in crystallizing various proteasome-inhibitor complexes. They subsequently obtained crystal structures for the native human proteasome and eight different inhibitor complexes at resolutions between 1.9 and 2.1 Å. The inhibitors sampled include drugs that are approved or in trial for cancer treatment. Science , this issue p. 594